3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Withdrawn
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
NET
1
Endocrine
1
Dermatologic
1
CNS
1
Conditions
Neuroendocrine Tumors
4
Pheochromocytoma
2
Paraganglioma
2
Vipoma
1
Neoplasms, Unknown Primary
1
Insulinoma
1
Gastro-enteropancreatic neuroendocrine tumor
1
Gastrinoma
1
Carcinoma, Merkel Cell
1
Carcinoid Tumor
1
Interventions
pembrolizumab
9
avelumab
9
Nivolumab
8
atezolizumab
4
Specimen Handling
4
durvalumab
3
cemiplimab
3
Radiotherapy
3
Magnetic Resonance Spectroscopy
3
Etoposide
3
Cyclophosphamide
3
Biopsy
3
ALT-803
3
talimogene laherparepvec
2
fludarabine phosphate
2
fludarabine
2
domatinostat
2
Radiosurgery
2
Ipilimumab
2
Cisplatin
2
Carboplatin
2
relatlimab
1
oblimersen
1
lutetium Lu 177 dotatate
1
lenvatinib
1
lanreotide
1
daromun
1
cabozantinib
1
antineoplaston AS 2-1
1
antineoplaston A10
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Phase 2
×
Carcinoma, Merkel Cell
×
177Lu-octreotide, DOTA(0)-Tyr(3)-
×
Clear all
NCT04276597
2023-03-10
PUTNET
Excel Diagnostics and Nuclear Oncology Center
Phase 2
Withdrawn